Comparison · NCT04163458-deaths
MENOPUR Liquid vs MENOPUR Powder: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. MENOPUR Liquid vs MENOPUR Powder: deaths from any cause. Trial comparisons, record NCT04163458-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04163458-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0187 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0189 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.0189 | 0.0187 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to harm | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | MENOPUR Liquid | MENOPUR liquid (including placebo to MENOPUR powder) initiated at a fixed dose of 225 international units (IU) for first five stimulation days. From stimulation Day 6, dosing could be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose was 450 IU/day and the minimum dose was 75 IU/day. The dosing could continue for a maximum of 20 days.~MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL: Solution for injection in pre-filled pen, subcutaneous administration~Placebo (for MENOPUR powder and solvent for solution for injection): Solution for injection in vials (powder and diluent); subcutaneous administration | 0 | 202 | EG000 |
| Group 2 | MENOPUR Powder | MENOPUR powder (including placebo to MENOPUR liquid) initiated at a fixed dose of 225 IU for first five stimulation days. From stimulation Day 6, dosing could be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose was 450 IU/day and the minimum dose was 75 IU/day. The dosing could continue for a maximum of 20 days.~MENOPUR powder and solvent for solution for injection, 75 IU: Solution for injection in vials (powder and diluent), subcutaneous administration~Placebo (for MENOPUR solution for injection in pre-filled pen): Solution for injection in pre-filled pen, subcutaneous administration | 0 | 199 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Adverse events were recorded from the time of signed informed consent for participation in the trial until the end-of-trial visit (up to approximately 6 months).
Source ClinicalTrials.gov
Trial
- Title
- Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)
- NCT number
- NCT04163458
- Phases
- PHASE3
- Conditions
- Infertility
- Interventions
MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL, MENOPUR powder and solvent for solution for injection, 75 IU, Placebo (for MENOPUR solution for injection in pre-filled pen), Placebo (for MENOPUR powder and solvent for solution for injection)
- Lead sponsor
- Ferring Pharmaceuticals
- Results first posted
- 2023-11-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04163458?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04163458-deaths